


Evermine 50 EES-KLES study

Study Highlights

- Principal Investigator: Dr. Suresh V. Patted
- It is a retrospective, single-arm, all-comers and single-center study to evaluate the 24-month clinical safety and performance of the Evermine 50 everolimus-eluting stent system (EES) in patients with coronary artery disease (CAD)
- The study demonstrated favourable clinical safety and performance profile of Evermine 50 EES in patients with CAD



❖ Study Design

A retrospective, single-centre, single-arm, all-comers study



A total of 171 patients were enrolled in this study



One investigational site across India



Clinical follow-up at 30 days

Telephonic follow-up at 6 months, 1 year and 2 years

❖ Study Results




Figure 1: Cardiac status, (%)




Figure 2: Disease vessel, (%)




Figure 3: Target vessel locations, (%)

❖ References

- 1) Clinical Trial Registry- India (CTRI) number: CTRI/2017/09/009939
<http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=20257&Enchid=&userName=Meril>
- 2) Patted SV. Real World Experience with Ultra-low Strut Thickness Everolimus Eluting DES – Evermine 50. INDIA LIVE 2017.
- 3) Patted SV. Biodegradable polymer Evermine 50™ everolimus eluting coronary stent system with ultrathin (50 µm) strut. Integrative Clinical Medicine. 2018, Volume 2(3): 1-2.
- 4) Patted SV. Clinical outcomes of ultrathin strut biodegradable polymer coated everolimus-eluting coronary stent system in treatment of patient with de novo coronary artery lesions. Euro PCR 2018.
- 5) Presented by Ashok Thakkar. Outcomes of Ultrathin Strut Biodegradable Polymer Coated Everolimus-Eluting Coronary Stent in Patients with Coronary Artery Disease. At TCT-2018.

- 6) Patted SV, Porwal S. One-year Clinical Outcomes After Percutaneous Coronary Intervention With Biodegradable Polymer Ultra-thin Strut Everolimus-Eluting Coronary Stent System. *AsiaIntervention* 2019;5:81-104.
- 7) Patted SV. Clinical outcomes of ultrathin strut biodegradable polymer-coated everolimus-eluting stent in patients with coronary artery disease. *ARYA Atherosclerosis journal*. 2020. Volume 16(3).